Clinical Trial Search

Primary: Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population — -54.1; -62.0; -54.5 Change in Hot Flush Count

Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…

Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale

Primary: Arterial Stiffness — 10.1; 14.8; 6.4; 12.7 mm Hg

Primary: Areal Bone Density by DXA — 0.88; 0.89 g/cm2

Primary: Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) — -54.515; -54.125; -44.389; -30.020 Hot Flushes per week — p=<0.0001

Primary: Arterial Compliance - Augmentation Index — 1.067 percentage of Arterial stiffness

Primary: Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months — 0.05; 0.06; 0.06; 0.066 Percent…

Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless

Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05

Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90

Primary: Inducible Myocardial Ischemia — -13.8; -7.0 percent changed in PCR/ATP ratio — p=0.36

Primary: Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism) — 24; 74; 21; 12 participants

Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…

Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled

Primary: Change in Six Minute Walk Distance — 42.69; 40.50; 37.65; 42.38 Meters — p=0.853

Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67

Primary: Behavioral & Mood Measure: Profile of Mood States (POMS) — 57.7; 55.5; -4.5; -0.1 units on a scale

Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min

Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04

Primary: Hot Flashes — 10.3; 7.944 scores on a scale

Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants

Primary: Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS) — 2.77; 2.78; 2.15 millimeters of mercury (mmHg)

Primary: Dual Energy X-ray Absorptiometry (DXA) Assessment of Lean Tissue Mass (LTM) — 53.1; 50.5 kilograms — p=<0.01

Primary: Change From Baseline in Weight — 0.1; 1.5 kilograms

Primary: Disease-specific Survival (DSS) (10-year Rates Reported) — 95; 96 percentage of participants — p=0.45

Primary: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event — 182; 190 Participants

Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale

Primary: Number of Participants Demonstrating Abstinence — 5; 4 Participants

Primary: Percent of Subjects With Testosterone Levels in the Normal Range. — 68.4 percentage of participants